A Phase II Two Cohort Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Sponsors Roche
- 03 Jul 2019 Planned End Date changed from 29 Mar 2023 to 28 Sep 2022.
- 03 Jul 2019 Planned primary completion date changed from 29 Mar 2023 to 28 Sep 2022.
- 04 Feb 2019 Status changed from not yet recruiting to recruiting.